Longitudinal Survey Analysis in Lymphoma Survivors

Lymphoma Clinical Trial

— CLEAR Stress  

Official title:

Coping With Lymphoma to Enhance Adjustment and Reduce Stress in Lymphoma Survivors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01469754
• Other study ID #: 1107011786
• Status: Completed
• Phase: N/A
• First received: November 8, 2011
• Last updated: May 1, 2014
• Start date: September 2011
• Est. completion date: September 2013

Study information

• Verified date: May 2014
• Source: Weill Medical College of Cornell University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Posttraumatic Stress Disorder (PTSD) is a well-documented phenomenon that occurs in cancer survivors. PTSD is known to cause problems with anxiety, depression, and quality of life. Furthermore, there is little treatment available for cancer survivors who suffer from PTSD.

Posttraumatic Growth, however, is a lesser known phenomenon that also occurs in cancer survivors. It is a positive psychological phenomenon that occurs in some people who have suffered a traumatic event--the people who are able to note a "greater appreciation for life", a "stronger relationship with their family/friends," or a "new found level of spirituality" are examples of instances of posttraumatic growth.

Coping with Lymphoma to Enhance Adjustment and Reduce Stress in Survivors (CLEAR Stress) is a study designed to compare the development of PTSD versus the development of Posttraumatic Growth in lymphoma patients at any stage of the cancer experience, regardless of treatment. The hypothesis is that posttraumatic growth, if it is significant, can reduce the impact of PTSD symptoms in the survivor.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 97
• Est. completion date: September 2013
• Est. primary completion date: July 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of Lymphoma (includes Waldenstrom's Macroglobulinemia)

• Can read/write/understand English without a translator

Exclusion Criteria:

• Currently Hospitalized

• Active Psychosis

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Coping
• Lymphoma
• Posttraumatic Growth
• Posttraumatic Stress Disorder
• Resilience
• Stress Disorders, Post-Traumatic
• Stress Disorders, Traumatic

Locations

Country	Name	City	State
United States	New York Presbyterian/Weill Cornell Center for Lymphoma and Myeloma	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Weill Medical College of Cornell University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Posttraumatic Growth		Measured at enrollment
Secondary	Posttraumatic Stress Disorder (PTSD)		Measured at Enrollment

External Links

•   WCMC Link to Study Description